A5066488972- Virus-based gene therapy research
- Cancer Research and Treatments
- CAR-T cell therapy research
- Immunotherapy and Immune Responses
- Neuroscience and Neural Engineering
- Advanced biosensing and bioanalysis techniques
- Mesenchymal stem cell research
- Ultrasound and Hyperthermia Applications
- CRISPR and Genetic Engineering
- Immune Cell Function and Interaction
- Viral gastroenteritis research and epidemiology
- Osteoarthritis Treatment and Mechanisms
- Gene expression and cancer classification
- Advanced Biosensing Techniques and Applications
- Periodontal Regeneration and Treatments
- RNA Interference and Gene Delivery
- Monoclonal and Polyclonal Antibodies Research
- Microfluidic and Bio-sensing Technologies
- Sarcoma Diagnosis and Treatment
- Neuroblastoma Research and Treatments
- Ultrasound Imaging and Elastography
- Knee injuries and reconstruction techniques
- Neurological disorders and treatments
- Organ and Tissue Transplantation Research
- Total Knee Arthroplasty Outcomes
Rice University
2021-2024
University of Tehran
2021-2022
Proinflammatory cytokines have been approved by the Food and Drug Administration for treatment of metastatic melanoma renal carcinoma. However, effective cytokine therapy requires high-dose infusions that can result in antidrug antibodies and/or systemic side effects limit long-term benefits. To overcome these limitations, we developed a clinically translatable delivery platform composed polymer-encapsulated human ARPE-19 (RPE) cells produce natural cytokines. Tumor-adjacent administration...
Background Mesenchymal stromal cells (MSCs) injection has been proposed as an innovative treatment for knee osteoarthritis (KOA). Since, allogeneic MSCs can be available off-the-shelf products, they are preferable in regenerative medicine. Among different sources MSCs, adipose-derived (AD-MSCs) appear to more available.Methods Three patients with KOA were enrolled this study. A total number of 100 × 106 AD-MSCs was injected intra-articularly, per affected knee. They followed up 6 months by...
Gene expression is a critical component of brain physiology, but monitoring this in the living represents major challenge. Here, we introduce new paradigm called recovery markers through insonation (REMIS) for noninvasive measurement gene with cell type, spatial, and temporal specificity. Our approach relies on engineered protein that are produced neurons exit into brain’s interstitium. When ultrasound applied to targeted regions, it opens blood-brain barrier releases these bloodstream. Once...
ABSTRACT Focused Ultrasound Blood-Brain Barrier Opening (FUS-BBBO) can deliver adeno-associated viral vectors (AAVs) to treat genetic disorders of the brain. However, such often affect large brain regions. Moreover, applicability FUS-BBBO in treatment brain-wide has not yet been evaluated. Herein, we evaluated transduction efficiency and safety opening up 105 sites simultaneously. Increasing number targeted increased gene delivery at each site. We achieved 60% cells with comparable majority...
Blood tests are among the most common clinical tools due to their low cost, simplicity, and ability observe many markers at once. However, currently, blood can only monitor a fraction of physiological processes that happen have serum marker. Here, we will present our work on development synthetic track gene expression in intact brain cells with simple test. The marker approach has several advantages. First, detection existing may be challenging levels blood. With marker, one design reporter...
ABSTRACT Understanding transcription profiles of living tissues is critical for biology and medicine. However, measurement the transcript levels typically done in homogenized post-mortem. Here, we present a new platform that enables non-invasive monitoring specific mRNA vivo , without tissue destruction. We achieved this by combining two cutting-edge tools - synthetic serum markers, called Released Markers Activity ( RMAs ), RNA-based sensors transcription. call IN-vivo Tracking ACtive...
Osteoarthritis is the second most common disorder after heart disease. This progressive degenerative disease affects knee joint more than any others. The exact etiology of osteoarthritis not clear, however, there are many predisposing factors such as obesity, age, gender, etc., that can increase incidence and prevalence this Early diagnosis in very important. Despite variety diagnostic methods, lack a valid reliable approach to detect early stages has always been challenge for researchers....
ABSTRACT Noninvasive efforts to map brain gene expression have been hampered by low sensitivity and limited access the brain. Here, we introduce a new platform that enables multiplexed, noninvasive, site-specific monitoring of through novel class engineered reporters called Released Markers Activity (RMAs). Instead detecting in less accessible brain, RMA exit from known region into blood, where they can be easily measured with biochemical techniques. Expressing RMAs at single site, typically...
ABSTRACT The brain is comprised of multiple regions performing distinct functions. Within each these regions, there are cell types that can affect physiology. Finally, within signaling pathways, that, when activated or inhibited, control the cell’s activity, and consequently function. For reasons, methods with regional, cell-type, molecular precision have been widely used in neuroscience. However, so far, achieving sustained over a region level specificity relied either on gene delivery...
Abstract Adeno-associated virus (AAV) vector-based gene therapies can be applied to a wide range of diseases. AAV expression last for months years, but vector re-administration may necessary achieve life-long treatment. Unfortunately, immune system response against these vectors is potentiated after the first administration, which prevents clinical use repeated administration AAVs. Reducing AAVs while minimizing immunosuppression would improve delivery efficiency and long-term safety. In...
<h3>Background</h3> Aldesleukin, recombinant human IL-2 has been approved by the FDA for treatment of melanoma and renal cancer. However, effective cytokine therapy is limited its short half-life in circulation severe adverse effects associated with high systemic exposure when administered iv. To overcome these limitations, Avenge Bio developed a localized delivery LOCOcyte<sup>TM</sup> platform comprised polymer encapsulated epithelial cells that produce potent immune effector molecules...
Abstract Recombinant IL-2 has been approved for the treatment of melanoma and renal cancer. However, therapy is limited by its short half-life in circulation associated toxicities that emerge as a result high systemic exposure. To overcome these limitations, we developed localized cytokine LOCOcyteTM platform composed allogeneic engineered cells which produce potent immune effector molecules local delivery with temporal regulation activity. Administration AVB-001 mice non-human primates...
Background Pro-inflammatory cytokines have been approved by the FDA for treatment of metastatic melanoma and renal carcinoma. 1 2 However, effective cytokine therapy is limited its short half-life in circulation severe adverse effects associated with high systemic exposure. 3 To overcome these limitations, we developed a clinically translatable localized delivery platform composed polymer encapsulated epithelial cells that produce natural (IL2, IL7, IL10, or IL12) temporal regulation....